First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

R. Giampieri; M. Puzzoni; B. Daniele; D. Ferrari; S. Lonardi; A. Zaniboni; L. Cavanna; G. Rosati; N. Pella; M.G. Zampino; P. Sozzi; D. Germano; V. Zagonel; C. Codecà; M. Libertini; R. Labianca; S. Cascinu; M. Scartozzi

doi:10.1038/bjc.2017.234

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

R. Giampieri, M. Puzzoni, B. Daniele, D. Ferrari, S. Lonardi, A. Zaniboni, L. Cavanna, G. Rosati, N. Pella, M.G. Zampino, P. Sozzi, D. Germano, V. Zagonel, C. Codecà, M. Libertini, R. Labianca, S. Cascinu, M. Scartozzi

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1099-1104
Number of pages	6
Journal	British Journal of Cancer
Volume	117
Issue number	8
DOIs	https://doi.org/10.1038/bjc.2017.234
Publication status	Published - 2017

Access to Document

10.1038/bjc.2017.234

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031047283&doi=10.1038%2fbjc.2017.234&partnerID=40&md5=c0e3bc7394c5e5d5c3ef948042ac8438

Cite this

Giampieri, R., Puzzoni, M., Daniele, B., Ferrari, D., Lonardi, S., Zaniboni, A., Cavanna, L., Rosati, G., Pella, N., Zampino, M. G., Sozzi, P., Germano, D., Zagonel, V., Codecà, C., Libertini, M., Labianca, R., Cascinu, S., & Scartozzi, M. (2017). First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. British Journal of Cancer, 117(8), 1099-1104. https://doi.org/10.1038/bjc.2017.234

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. / Giampieri, R.; Puzzoni, M.; Daniele, B.; Ferrari, D.; Lonardi, S.; Zaniboni, A.; Cavanna, L.; Rosati, G.; Pella, N.; Zampino, M.G.; Sozzi, P.; Germano, D.; Zagonel, V.; Codecà, C.; Libertini, M.; Labianca, R.; Cascinu, S.; Scartozzi, M.

In: British Journal of Cancer, Vol. 117, No. 8, 2017, p. 1099-1104.

Research output: Contribution to journal › Article › peer-review

Giampieri, R, Puzzoni, M, Daniele, B, Ferrari, D, Lonardi, S , Zaniboni, A, Cavanna, L, Rosati, G, Pella, N, Zampino, MG, Sozzi, P, Germano, D, Zagonel, V, Codecà, C, Libertini, M, Labianca, R, Cascinu, S & Scartozzi, M 2017, 'First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial', British Journal of Cancer, vol. 117, no. 8, pp. 1099-1104. https://doi.org/10.1038/bjc.2017.234

Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S , Zaniboni A et al. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. British Journal of Cancer. 2017;117(8):1099-1104. https://doi.org/10.1038/bjc.2017.234

Giampieri, R. ; Puzzoni, M. ; Daniele, B. ; Ferrari, D. ; Lonardi, S. ; Zaniboni, A. ; Cavanna, L. ; Rosati, G. ; Pella, N. ; Zampino, M.G. ; Sozzi, P. ; Germano, D. ; Zagonel, V. ; Codecà, C. ; Libertini, M. ; Labianca, R. ; Cascinu, S. ; Scartozzi, M. / First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. In: British Journal of Cancer. 2017 ; Vol. 117, No. 8. pp. 1099-1104.

@article{822af07e9e3e4a44b7d6d622613b1ba3,

title = "First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial",

author = "R. Giampieri and M. Puzzoni and B. Daniele and D. Ferrari and S. Lonardi and A. Zaniboni and L. Cavanna and G. Rosati and N. Pella and M.G. Zampino and P. Sozzi and D. Germano and V. Zagonel and C. Codec{\`a} and M. Libertini and R. Labianca and S. Cascinu and M. Scartozzi",

note = "Cited By :1 Export Date: 5 March 2018",

year = "2017",

doi = "10.1038/bjc.2017.234",

language = "English",

volume = "117",

pages = "1099--1104",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

AU - Giampieri, R.

AU - Puzzoni, M.

AU - Daniele, B.

AU - Ferrari, D.

AU - Lonardi, S.

AU - Zaniboni, A.

AU - Cavanna, L.

AU - Rosati, G.

AU - Pella, N.

AU - Zampino, M.G.

AU - Sozzi, P.

AU - Germano, D.

AU - Zagonel, V.

AU - Codecà, C.

AU - Libertini, M.

AU - Labianca, R.

AU - Cascinu, S.

AU - Scartozzi, M.

N1 - Cited By :1 Export Date: 5 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1038/bjc.2017.234

DO - 10.1038/bjc.2017.234

M3 - Article

VL - 117

SP - 1099

EP - 1104

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -